PepGen Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $23.1 million, a decrease from a net loss of $28.3 million in the same period last year. The company's total operating expenses for the quarter were $23.9 million, down from $30.4 million in the prior year, primarily due to a significant reduction in research and development costs, which fell from $25.1 million to $18.4 million. This decline was attributed to decreased manufacturing costs and the winding down of clinical trials for its discontinued product candidate, PGN-EDO51. General and administrative expenses remained relatively stable, increasing slightly from $5.4 million to $5.6 million.
In terms of financial position, PepGen's total assets decreased to $102.2 million as of June 30, 2025, down from $150.9 million at the end of 2024. The company's cash and cash equivalents, along with marketable securities, totaled $74.7 million, a significant decline from $123.8 million at the end of the previous fiscal year. The accumulated deficit increased to $324.8 million, reflecting ongoing operational losses since the company's inception. The company has indicated that its existing cash resources are expected to fund operations into the second quarter of 2026, but it will need to raise additional capital to continue its operations beyond that point.
Strategically, PepGen announced the voluntary discontinuation of its PGN-EDO51 program for Duchenne muscular dystrophy (DMD) in May 2025, following unsatisfactory clinical trial results. The company plans to focus its efforts on advancing PGN-EDODM1, a candidate for the treatment of myotonic dystrophy type 1 (DM1), which has shown promising preclinical results. The ongoing clinical trials for PGN-EDODM1 include the FREEDOM study, which is currently enrolling participants in multiple countries, and the FREEDOM2 study, which is set to expand into additional geographies pending regulatory approvals.
Operationally, PepGen's workforce has seen an increase, with the company planning to expand its headcount to support its development and regulatory capabilities. The company is also exploring additional indications for its oligonucleotide therapies, aiming to leverage its Enhanced Delivery Oligonucleotide platform. However, the company faces significant challenges, including the need for substantial funding to support its research and development activities and the potential impact of ongoing litigation related to its previous product candidate. The outlook remains cautious, with management expressing substantial doubt about the company's ability to continue as a going concern without securing additional financing.
About PepGen Inc.
PepGen Inc. is a biotechnology company developing oligonucleotide therapeutics using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. Focused on neuromuscular and neurological diseases like Duchenne muscular dystrophy and myotonic dystrophy, it leverages cell-penetrating peptides to improve tissue delivery and efficacy. Its pipeline includes clinical-stage exon-skipping and splicing correction programs, aiming to address genetic root causes with enhanced safety, potency, and scalability.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.